European Commission claims pharma competition success
The proportion of problematic patent settlements in the pharmaceutical industry has fallen, even though the number of settlements has grown, according to the European Commission
In a statement published on January 31, the Commission said
that its third annual survey had found that 11% of antitrust
settlements were potentially problematic from an antitrust
point of view, compared to 21% when the pharmaceutical sector
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.